Marina Biotech Achieves Significant Improvements in siRNA Delivery via New DiLA2-Based Compositions
Data Demonstrate a 10-Fold Improvement for Knockdown of a Liver Target
Read more on Marketwire
Marina Biotech Announces Allowance of Fundamental RNAi Delivery Patent From U.S. Patent Office
BOTHELL, WA–(Marketwire – 08/30/10) – Marina Biotech, Inc. (NASDAQ: MRNA – News ), a leading RNAi-based drug discovery and development company, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for patent application U.S. 11/745,003 broadly covering amphoteric liposomal formulations, including the Company’s proprietary SMARTICLES technology, for delivery …
Read more on Marketwire via Yahoo! Finance
Elan in talks with investors over sale of drug delivery unit
BIOTECH GROUP Elan has had talks with investors about the possible sale of its Athlone drug delivery business over the last month.
Read more on The Irish Times
Powered by Yahoo! Answers
